1617

INN
VORTIOXETINE

NERVOUS SYSTEM
TREATMENT OF MAJOR DEPRESSIVE DISORDER
ENHANCEMENT OF SEROTONERGIC ACTIVITY
INHIBITION OF THE REUPTAKE OF SEROTONIN (5-HT)
SEROTONIN TRANSPORTER INHIBITOR (KI=1.6 NANOMOLAR)
5-HT3 RECEPTOR ANTAGONIST (KI=3.7 NANOMOLAR) AND 5-HT1A RECEPTOR AGONIST (KI=15 NANOMOLAR), 5-HT7 (KI=19 NM), 5-HT1D (KI=54 NM), AND 5-HT1B (KI=33 NM), RECEPTORS AND IS A 5-HT3, 5-HT1D, AND 5-HT7 RECEPTOR ANTAGONIST, 5-HT1B RECEPTOR PARTIAL AGONIST, AND 5-HT1A RECEPTOR AGONIST.

ORAL

F 75 PERCENT
VD 2600 LITER
Cl 27.3 LITER / HOUR (EQN)
PPB 98 PERCENT
t1/2 66 HOUR

SLIGHTLY SOLUBLE IN WATER

PDB
8BLA (HUMAN SEROTONIN 5-HT3A RECEPTOR IN COMPLEX WITH VORTIOXETINE (DETERGENT, ECD ONLY, ACTIVE, DISTORTED CONFORMATION))

Ligand code = VTX (link to the list of PDB complexes)

Download experimental 3D coordinates of VTX with added hydrogens